Special Issue

Strategies for the Discovery of Antivirals against Respiratory RNA Viruses

Message from the Guest Editor

Emerging and re-emerging respiratory RNA viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and G4 swine influenza virus, have become a great threat to global public health. With the exception of influenza A and B viruses and respiratory syncytial virus (RSV), there are no FDA-approved, virus-specific drugs for the treatment of infections with other human respiratory viruses, such as coronaviruses, rhinoviruses, and parainfluenza viruses. There is an urgent need for the development of novel antivirals and the identification of drug targets derived from either viral proteins or host factors, by which therapeutic effects could be induced efficiently and sufficiently. This Special Issue focuses on recent progress in antiviral discovery, investigation of the mode-of-action, target validation, and establishment of drug screening methods. We hope that this Special Issue will allow researchers to share scientific insights to help find a therapeutic way to treat human respiratory virus infection-mediated diseases in the ongoing pandemic situation or in order to be prepared for possible upcoming pandemics.

Guest Editor

Dr. Meehyein Kim

Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology, Daejeon, Korea

Deadline for manuscript submissions

closed (20 December 2021)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/55500

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

MDPI

About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).